本周关注点 交易信息汇总：迈威生物因收盘价格涨幅达到15%首次上榜龙虎榜 公司公告汇总：董事长提议回购股份，金额不低于2500万元不超过5000万元 交易信息汇总 迈威（上海）生物科技股份有限公司于2025年6月4日收到公司董事长、总经理刘大涛先生提交的关于提 议公司回购股份的函。提议内容包括：回购股份种类为公司已发行的人民币普通股（A股），用途为未 来全部用于员工持股计划或股权激励；回购方式为通过上海证券交易所交易系统以集中竞价交易方式进 行；回购资金总额不低于人民币2500万元（含），不超过人民币5000万元（含），资金来源为自有资金 和/或股票回购专项贷款；回购价格不超过人民币35.00元/股（含）；回购期限为自公司董事会审议通过 本次回购方案之日起12个月内。刘大涛先生在提议前6个月内不存在买卖本公司股份的情况，在本次回 购期间暂无增减持公司股份计划。刘大涛先生承诺将推动公司尽快召开董事会审议回购股份事项，并在 董事会上投赞成票。公司将尽快制定合理可行的回购股份方案，履行审批程序并及时披露信息。上述回 购事项尚存在不确定性，敬请投资者注意投资风险。 截至2025年6月6日收盘，迈威生物（688062） ...

迈威生物6月6日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 沪股通专用 | 3688.06 | | 机构专用 | 2173.64 | | 机构专用 | 2086.78 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1955.79 | | 海通证券股份有限公司汕头中山中路证券营业部 | 1769.51 | | 卖出营业部名称 | 卖出金额(万元) | | 民生证券股份有限公司信阳新五大道证券营业部 | 2272.68 | | 沪股通专用 | 1921.88 | | 海通证券股份有限公司深圳红岭北路证券营业部 | 1597.03 | | 中信证券股份有限公司上海分公司 | 1308.04 | | 国元证券股份有限公司芜湖文化路证券营业部 | 1156.87 | 6月6日迈威生物（688062）收盘价27.90元，收盘上涨17.67%，全天换手率13.06%，振幅21.65%，成交 额6.92亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.99亿元， 其中，买入成交额为1.1 ...

Investment Rating - The report suggests a positive outlook for the pharmaceutical sector, indicating that the industry is expected to experience a sustained recovery and structural opportunities remain available [5][41]. Core Insights - The 2025 ASCO conference highlighted a record number of domestic new drug entries, with 74 abstracts accepted, including 34 oral presentations and 32 rapid oral presentations, marking a significant increase from 55 entries in 2024 [7][11]. - Several domestic innovative drugs demonstrated promising clinical data, particularly in oncology, with notable advancements in treatments for advanced non-small cell lung cancer, colorectal cancer, and pancreatic cancer [11][12][15]. - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 34.47 compared to 12.56 for the CSI 300, indicating a premium of 174.35% over the index [20][41]. Monthly Policy and Industry Updates - The ASCO 2025 conference showcased a record number of domestic new drugs, with significant clinical data released that attracted market attention [7][11]. - Multiple domestic new drugs reported impressive data, particularly in the field of cancer treatment, indicating breakthroughs in various therapies [11][12][15]. Industry Data Dynamics - The pharmaceutical sector has shown weaker performance compared to the CSI 300 index, with a decline of 14.00% in the SW pharmaceutical and biological index from early 2023 to June 5, 2025, while the CSI 300 index increased by 0.15% [20]. - The revenue growth of the pharmaceutical manufacturing industry has slowed due to the pandemic's impact, but it continues to grow faster than GDP [23]. - Outpatient expenses have risen due to the pandemic, while inpatient costs have been effectively controlled, reflecting the impact of healthcare reforms [26]. Investment Recommendations - The report emphasizes the potential for growth in the pharmaceutical sector, particularly in innovative drugs and their supply chains, as well as in medical devices and third-party medical testing [41][42]. - Specific companies to watch include innovative drug manufacturers and those involved in medical device exports, as well as companies benefiting from ongoing healthcare reforms [41][42][43].

Investment Rating - The report suggests a positive outlook for the pharmaceutical sector, indicating that the industry is expected to experience a sustained recovery and structural opportunities remain available [5][41]. Core Insights - The 2025 ASCO conference highlighted a record number of domestic new drug entries, with 74 abstracts accepted, including 34 oral presentations and 32 rapid oral presentations, marking a significant increase from 55 entries in 2024 [7][11]. - Several domestic innovative drugs demonstrated promising clinical data, particularly in oncology, with notable advancements in treatments for advanced non-small cell lung cancer, colorectal cancer, and pancreatic cancer [11][12][15]. - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 34.47 compared to 12.56 for the CSI 300, indicating a premium of 174.35% over the index [20][41]. Monthly Policy and Industry Updates - The ASCO 2025 conference showcased a record number of domestic new drugs, with significant clinical data released that attracted market attention [7][11]. - Multiple domestic drugs reported impressive results, particularly in cancer treatment, with specific drugs showing superior efficacy compared to existing therapies [11][12][15]. Industry Data Dynamics - The pharmaceutical sector has shown weaker performance compared to the CSI 300 index, with a decline of 14.00% in the SW pharmaceutical and biological index from early 2023 to June 5, 2025, while the CSI 300 index increased by 0.15% [20]. - The revenue growth of the pharmaceutical manufacturing industry has slowed due to the pandemic's impact, but it continues to grow faster than GDP [23]. - Outpatient expenses have risen due to the pandemic, while inpatient costs have been effectively controlled [26]. Investment Recommendations - The report emphasizes the potential for growth in the pharmaceutical sector, particularly in innovative drugs and their supply chains, as well as in medical devices and third-party medical testing [41][42]. - Specific companies are highlighted for their strong positions in the market, including those involved in innovative drug development and medical device manufacturing [41][42][43].

Group 1 - A-shares experienced a decline on June 6, with the Sci-Tech Medicine Index ETF (588700) showing a fluctuation, down 0.45% and with a turnover rate exceeding 8%, and a trading volume over 18 million [1] - The Sci-Tech Medicine Index ETF closely tracks the Shanghai Stock Exchange Sci-Tech Board Biomedicine Index, which selects 50 large-cap companies in biomedicine and related fields, reflecting the overall performance of representative biomedicine companies listed on the Sci-Tech Board [1] - Notable stocks within the ETF include Maiwei Biotech-U, which rose over 3%, along with several others such as Dongfang Bio, Borui Pharma, and Shenzhou Cell, indicating active trading in the sector [1] Group 2 - The National Healthcare Security Administration has revised the medical price and procurement credit evaluation system to combat improper trading behaviors like commercial bribery, aiming to enhance market integrity and resource allocation [2] - Longcheng Securities suggests that the frequent favorable policies for the pharmaceutical sector may lead to a steady recovery in industry sentiment, particularly in the hospital market, which has been affected by previous anti-corruption measures [2] - The focus on innovative therapies is expected to drive significant growth, with domestic BIC/FIC innovative drugs improving in quantity and quality, indicating a broad space for domestic innovation and international expansion [2] Group 3 - Zhongtai Securities emphasizes the importance of embracing innovation, highlighting record-breaking BD transaction amounts and strong performances of Chinese pharmaceutical companies at ASCO, suggesting a potential revaluation of the sector [3] - The recommendation includes actively investing in segments expected to recover, such as CRO&CDMO, upstream research, specialty raw materials, chain pharmacies, and branded OTC products [3] - The overall business situation for Q2 is anticipated to become clearer, providing opportunities for strategic investments in the pharmaceutical industry [3]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]

迈威（上海）生物科技股份有限公司 关于收到公司董事长、总经理提议公司回购股份的提 示性公告 证券代码：688062 证券简称：迈威生物 公告编号：2025-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"） 于 2025 年 6 月 4 日收到公司董事长、总经理刘大涛先生提交的《关于提议迈威 （上海）生物科技股份有限公司回购公司股份的函》，提议内容如下： 一、 提议人的基本情况及提议时间 1、提议人：公司董事长、总经理刘大涛先生 2、提议时间：2025 年 6 月 4 日 二、 提议人提议回购股份的原因和目的 公司董事长、总经理刘大涛先生基于对公司未来持续稳定发展的信心，以及 对公司股票长期投资价值的认可，为增强投资者对公司的投资信心，推动公司股 票价格向长期内在价值的合理回归，同时促进公司稳定健康发展，有效地将股东 利益、公司利益和员工个人利益紧密结合，提议通过上海证券交易所交易系统以 集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票。 ...

Core Viewpoint - The company plans to repurchase a portion of its issued A-shares through a centralized bidding trading method on the Shanghai Stock Exchange, with a total repurchase fund of no less than RMB 25 million and no more than RMB 50 million, at a price not exceeding RMB 35 per share [1] Group 1 - The repurchased shares will be used for employee stock ownership plans or equity incentives at an appropriate time in the future [1] - If the shares are not fully utilized within three years after the announcement of the repurchase results, they will be canceled [1] - The source of the repurchase funds will be from the company's own funds and/or special loans for stock repurchase [1] Group 2 - The proposal is valid for 12 months from the date of approval by the board of directors [1]

Group 1 - The Chinese innovative pharmaceutical industry is experiencing an unprecedented revaluation, with the innovative drug index rising over 20% and the Hong Kong innovative drug index increasing by more than 45% this year [1][2] - Institutions have shown heightened interest in the innovative drug sector, with numerous companies such as BeiGene and I-Mab being heavily researched by various institutions [1][3] - The focus of institutional research has shifted from generic drugs and raw materials to cutting-edge areas like ADCs, bispecific antibodies, and cell therapies, indicating a growing interest in clinical data and international progress [4][5] Group 2 - The recent surge in the innovative drug sector is attributed to the culmination of years of investment and development, with many projects now reaching commercialization [5][6] - The improvement in liquidity and the influx of foreign capital have significantly boosted the performance of Hong Kong innovative drug stocks, with net purchases exceeding 600 billion yuan this year [6][7] - The next three years are expected to be critical for the Chinese innovative drug industry, with 2025 marking a pivotal year for revenue growth, profitability, and valuation increases [8][9] Group 3 - The innovative drug sector is anticipated to remain a key focus within the pharmaceutical industry, with particular attention on companies that are successfully entering overseas markets and those that are experiencing significant domestic sales growth [9]

Core Insights - The National Medical Products Administration approved 11 innovative drugs recently, with 10 coming from listed companies, indicating a significant advancement in China's pharmaceutical sector [1][4] - The approval of these drugs marks a pivotal moment for the industry, as it transitions into a phase of realizing the results of extensive research and development efforts [7][8] Group 1: Drug Approvals and Innovations - Among the approved drugs, several are the first of their kind in China, including Bai Jie Shen Zhou's injection of Zhenida Monoclonal Antibody, which is the first HER2 dual-target drug approved for cholangiocarcinoma [4][5] - Heng Rui Pharmaceutical's Apixaban is a multi-target tyrosine kinase inhibitor approved for use in advanced solid tumors, showcasing innovative treatment mechanisms [4][5] - The approval of Zai Jing Pharmaceutical's Jikaxitinib marks the first domestic JAK inhibitor for treating myelofibrosis, providing new options for patients with rare blood cancers [5][6] Group 2: Market Trends and Investment Opportunities - The innovative drug sector has seen a strong market performance, with 53 stocks hitting the daily limit up, indicating heightened investor interest [2][7] - Analysts predict that 2025 will be a transformative year for the pharmaceutical industry, characterized by increased revenue, profitability, and valuation improvements [1][7] - The Hong Kong innovation drug index has seen significant capital inflow, with over 200 million yuan in net inflow over the past 20 trading days, reflecting strong market sentiment [2][8] Group 3: Challenges and Future Outlook - Despite the positive developments, the innovative drug industry faces challenges such as high uncertainty in commercialization and intense competition among similar products [7][8] - The industry is supported by favorable policies and the growth of commercial health insurance, which enhances the payment environment for innovative drugs [8]